Although clinical trial evidence proving ESCMs therapeutic effect on cancer remains limited, there are currently ongoing clinical trials investigating this
Furthermore, the identification of this phenotype may contribute to the development of future research directions, including biomarker discovery, longitudinal phenotyping studies, and targeted therapeutic interventions focused on aging biology
IF youre unable to, dont worry
5, 1116, 18, 23, 25, 26 in the associated source data file
These linkers do not release the drug until the ADC is internalized and the antibody component is degraded within the lysosome, ensuring that the cytotoxic agent is not unleashed at off-target sites
Sala A, Mattano LA, Barr RD